STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. — المؤلف: Reilley, Matthew J — Journal for immunotherapy of cancer 20191025

المؤلف

Reilley, Matthew J

النشر

Journal for immunotherapy of cancer 20191025

الوصف

119 p.

الموضوعات

Adult؛ Aged؛ Aged, 80 and over؛ Female؛ Humans؛ Lymphoma؛ Male؛ Middle Aged